FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended ...

The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

The end of production at one of pharmaceutical firm GlaxoSmithKline's (GSK) UK factories is a "sad day", a former worker has said. The site in Ulverston, Cumbria, opened more than 75 years ago and ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults ...

The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.

As per the deal, GlaxoSmithKline will pay the vaccine maker up to $1.2 billion more if certain milestones are arrived at in Affinivax's impending clinical trials for a new pneumococcal vaccine.